Drug-eluting stents yield better outcomes than bare-metal ones

Sometimes known as medication-coated stents, drug-eluting stents are tiny tubes used to open narrowed arteries and slowly release a drug to prevent scar tissue growth. Although they have been universally accepted as more superior than more traditional, bare-metal stents, there is limited data comparing the generalized use of both stents, said lead researcher J. Dawn Abbott, M.D., a cardiologist at Rhode Island Hospital.

“Considering that drug-eluting stents are being used in the vast majority of stent procedures, its reassuring to find that they yield better outcomes than bare-metal stents when used in routine clinical practice,” said Abbott, who’s also an assistant professor of medicine at The Warren Alpert Medical School of Brown University.

Using broad geographic data from the National Heart, Lung and Blood Institute (NHLBI) Dynamic Registry, Abbott and her team compared outcomes for patients who underwent percutaneous coronary intervention – or angioplasty – and were treated with stents. One group received drug-eluting stents while a similar group received bare-metal stents when they were used more broadly before the commercialization of drug-eluting stents. Although separated in time by a few years, no other technologic advances other than drug-eluting stents occurred between recruitment of both groups of patients.

The researchers found that for at least up to one year, the use of drug-eluting stents in standard clinical practice was not associated with any excess risk of death or heart attack compared with bare-metal stents, even in patients with complex heart lesions. The cumulative death and heart attack rate in patients receiving drug-eluting stents was 7.6 percent compared to 8.7 percent in those treated with bare-metal stents.

Patients treated with drug-eluting stents also had a substantial reduction in clinically-driven target vessel revascularization (repeat angioplasty or bypass surgery of the target vessel) compared with patients who received bare-metal stents (5 percent vs. 8.7 percent). Furthermore, the durability of the initial angioplasty was found to be enhanced with drug-eluting stents.

“These findings confirm the safety and effectiveness of drug-eluting stents out to one year, but we are continuing to follow these patients to assess for possible late complications related to the stent implantation,” said senior author David O. Williams, M.D., a cardiologist at Rhode Island Hospital and a professor of medicine at Alpert Medical School.

This analysis compared 1,460 patients enrolled in the NHLBI Dynamic Registry in 2004 who received at least one drug-eluting stent and 1,760 patients who enrolled just before the approval of drug-eluting stents (2001 to 2002) and received at least one bare-metal stent. Researchers looked at lesion characteristics and procedural outcomes and both in-hospital and clinical outcomes after one year. All patients had also undergone angioplasty at selected clinical centers in North America. The study included drug-eluting stents that released either sirolimus or paclitaxel.

Source: Lifespan.org

Best use of drug-eluting stents
Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction. The use of drug-eluting stents necessitates extended treatment with dual antiplatelet therapy (aspirin plus thienopyridine) which may cause bleeding complications and interferes with or even precludes surgery in case this is needed.
Study: Bypass better than stents in long term
(AP) -- For heart patients with clogged arteries, the choice between bypass surgery or an angioplasty may come down to one question: How many procedures would you like to have? In research presented Monday at the European Society of Cardiology meeting in Munich, experts concluded that while bypass surgery and angioplasty offer comparable results, patients who have angioplasties are twice as likely to require another procedure within a year.
Tiny 3-D ultrasound probe guides catheter procedures
An ultrasound probe small enough to ride along at the tip of a catheter can provide physicians with clearer real-time images of soft tissue without the risks associated with conventional x-ray catheter guidance.
Risk of repeat attacks in heart patients causes concern for doctors
An international study, led by the University of Edinburgh, raises concerns that some patients may not be receiving the optimum medical treatment and follow-up care because doctors are misjudging the risk of a further heart attack.
More aortic chest aneurysms being treated with less-invasive stents
An estimated 60,000 Americans are walking around with time bombs in their chests called thoracic aortic aneurysms. At any time, their main chest artery could suddenly burst open, causing massive internal bleeding that is almost always fatal.
Study points to potential new use for Viagra
A "basic science" breakthrough by Queen's University researchers into regulating a single enzyme may lead to new drug therapies that will help prevent heart attacks and strokes.
Stent grafts: a better way to treat blunt trauma injuries
Endovascular repair—fixing an injury in a blood vessel from inside that vessel—is a better option for individuals who receive highly lethal injuries from high-speed collisions or falls (together referred to as blunt trauma) and is shown to save more lives and nearly eliminate paraplegia (the loss of the ability to move and/or feel both legs), a complication of surgical repair for thoracic aortic aneurysms.
Just dive in: Natural product hybrid provides antimicrobial and cell-resistant surfaces
(PhysOrg.com) -- Infections following treatment in clinics, retirement homes, and long-term care facilities are a grave problem for patients, and resistant germs can be particularly devastating.

Drug-eluting stents yield better outcomes than bare-metal ones

Related stories:

News discussion: